<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405535</url>
  </required_header>
  <id_info>
    <org_study_id>04I/C06</org_study_id>
    <nct_id>NCT00405535</nct_id>
  </id_info>
  <brief_title>Adjunctive Glycine for Obsessive Compulsive Disorder</brief_title>
  <official_title>Adjunctive Glycine for Obsessive Compulsive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nathan Kline Institute for Psychiatric Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Obsessive Compulsive Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Nathan Kline Institute for Psychiatric Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether individuals with obsessive compulsive
      disorder who will take a preparation of the amino acid glycine in addition to their current
      treatment, may experience improvement in their symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with
      the best of currently available treatments. Some evidence suggests the the neurotransmitter
      glutamate may be a useful target for new treatments for OCD. The amino acid glycine, if given
      orally in adequate dosages, can have specific effects on one particular glutamate receptor
      molecule in the brain, that might be helpful with OC symptoms. This randomized, double-blind
      protocol will have study participants who suffer with OCD take either a glycine preparation
      or placebo for 12 weeks. Clinical measures (e.g., Y-BOCS, NIMH-OC) will be recorded at each
      visit to determine whether those taking the glycine experience clinical benefit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Y-BOCS (Yale-Brown Obsessive Compulsive Scale)</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>NIMC-OC scale</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Improvement</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QLS(Quality of Life Scale)</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale</measure>
    <time_frame>12 weeks after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Obsessive Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>glycine powder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo powder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glycine</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of OCD present for at least 1 year

          -  Male or female, age 18 to 65

          -  Stable medication regimen for 12 weeks prior to study entry

          -  at least moderately severe OC symptoms

        Exclusion Criteria:

          -  Active substance use disorder within the last 6 months

          -  Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder,
             Tourette Disorder, schizotypal personality disorder

          -  Hoarding as the principal OCD symptom

          -  Insulin-dependent diabetes mellitus

          -  Pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William M Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nathan Kline Institute for Psychiatric Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Nathan Kline Institute for Psychiatric Research</name>
      <address>
        <city>Orangeburg</city>
        <state>New York</state>
        <zip>10962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 28, 2006</study_first_submitted>
  <study_first_submitted_qc>November 28, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>December 15, 2016</last_update_submitted>
  <last_update_submitted_qc>December 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2016</last_update_posted>
  <keyword>OCD</keyword>
  <keyword>Obsessive Compulsive Disorder</keyword>
  <keyword>Glycine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

